Trial · NCT04737343
Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated Vasculitis
NCT04737343, Not applicable, Unknown, Chinese SLE Treatment And Research Group
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated Vasculitis. Trials, record NCT04737343. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04737343
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated Vasculitis
- NCT number
- NCT04737343
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 114 participants, estimated
- Lead sponsor
- Chinese SLE Treatment And Research Group
- Conditions
- ANCA Associated Vasculitis, Maintenance Therapy
- Interventions
- Leflunomide, Azathioprine Tablets
- First posted
- 2021-02-03
- Last updated
- 2021-11-30
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | the percentage of patients with major relapse in 18 months follow-up time | from inclusion to the end of the study, 18 months in total | the percentage of patients with major relapse (re-appearance or worsening of disease with a BVAS \>0 and involvement of at least one major organ, a life-threatening manifestation, or both) at month 18 |
| Secondary | The rate of minor relapse of the AZA and LEF treatment group in 18 months. | from inclusion to the end of the study, 18 months in total | The rate of minor relapse (reappearance or worsening of disease with a BVAS \>0, not corresponding to a major relapse but requiring mild treatment intensification) of the AZA and LEF treatment group. |
| Secondary | The rate of adverse events and their severity in both LEF and AZA treated patients during 18 months of the study period. | from inclusion to the end of the study, 18 months in total | 2\. The rate of adverse events and their severity(Severe events were defined as the adverse events of grade 3 or 4, deaths caused by any cause, cancers, side effects that necessitate hospitalization) in both LEF and AZA treated patients during the study period. |
| Secondary | Patients progress to ESRD at the end of the study | from inclusion to the end of the study, 18 months in total | Patients progress to ESRD at the end of the study |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04737343
GET https://conductscience.org/api/trials/v1/NCT04737343/registered